Novel automated blood separations validate whole cell biomarkers

PLoS ONE

Volumn 6, Issue 7, 2011, Pages

  Burger, Douglas E ^a   Wang, Limei ^a   Ban, Liqin ^a   Okubo, Yoshiaki ^a   Kühtreiber, Willem M ^a   Leichliter, Ashley K ^a   Faustman, Denise L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ANTIGEN SPECIFICITY; ARTICLE; AUTOMATION; BIOASSAY; BLOOD ANALYSIS; BLOOD BASED MAGNETIC SEPARATION METHOD; CELL SEPARATION; CELL VIABILITY; COMPUTER PROGRAM; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; LABOR; LYMPHOCYTE; LYMPHOCYTE SUBPOPULATION; MAGNETIC SEPARATION; MAGNETISM; MAJOR CLINICAL STUDY; MANUAL FICOLL GRADIENT SEPARATION; PERIPHERAL LYMPHOCYTE; PURIFICATION; T LYMPHOCYTE; WHOLE CELL; ECONOMICS; INSTRUMENTATION; MAGNETIC FIELD; METABOLISM; METHODOLOGY; REPRODUCIBILITY; TIME;

AUTOMATION; BIOLOGICAL MARKERS; CELL SEPARATION; HUMANS; LYMPHOCYTES; MAGNETIC FIELDS; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 79960675810     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022430     Document Type: Article

References (16)

1. FDA Website. Critical Path Opportunities Report (2006) Available: http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/CriticalPathIniative/CriticalPathOpportunitiesReports/UCM077254.pdf. Accessed 2011 Jun 28.
2. Anonymous, (2010) Evaluation of biomarkers and surrogate endpoints in chronic disease. Consenus Report Washington, DC Institute of Medicine May 12, 2010.
3. Anonymous, (2007) Cancer Biomarkers: The Promises and Challenges of Improving Detection and Treatment. Consensus Report Washington, DC Institute of Medicine March 29, 2007.
4. Rosenberg R, Gertler R, Friederichs J, Fuehrer K, Dahm M, et al. (2002) Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood. Cytometry 49: 150-158.
5. Baker MK, Mikhitarian K, Osta W, Callahan K, Hoda R, et al. (2003) Molecular detection of breast cancer cells in the peripheral blood of advanced-stage breast cancer patients using multimarker real-time reverse transcription-polymerase chain reaction and a novel porous barrier density gradient centrifugation technology. Clinical Cancer Research 9: 4865-71.
6. Gilliam B, Riedel D, Redfield R, (2011) Clinical use of CCR5 inhibitors in HIV and beyond. Journal of Translational Medicine 9, S9.
7. Ban L, Zhang J, Wang L, Kühtreiber W, Burger D, et al. (2008) Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc Natl Acad Sci U S A 105: 13644-649.
8. Lissina A, Ladell K, Skowera A, Clement M, Edards E, et al. (2009) Protein kinase inhibitors substantially improve the physical detection of T-cells with peptide-MHC tetramers. J Immunol Methods 340: 11-24.
9. Noble PB, Cutts JH, (1967) Separation of blood leukocytes by Ficoll gradient. Can Vet J 8: 110-111.
10. Hook GR, Hosseini JM, Elin RJ, (1988) Density gradients for isolation of mononuclear blood cells for magnesium analysis by electron probe X-ray microanalysis. Magnesium 7: 1-5.
11. Hokland P, Heron I, (1980) The Isopaque-Ficoll method re-evaluated: selective loss of autologous rosette-forming lymphocytes during isolation of mononuclear cells from human peripheral blood. Scand J Immunol 11: 353-6.
12. Kühtreiber WM, Kodama S, Burger DE, Dale EA, Faustman DL, (2005) Methods to characterize lymphoid apoptosis in a murine model of autoreactivity. J Immunol Methods 306: 137-50.
13. Lin SJ, Chao HC, Yan DC, Huang YJ, (2002) Expression of adhesion molecules on T lymphocytes in young children and infants--a comparative study using whole blood lysis or density gradient separation. Clin Lab Haematol 24: 353-59.
14. Trusheim MR, Berndt ER, Douglas FL, (2007) Stratifed medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nature Reviews Drug Development 6: 287-93.
15. Editorial, (2010) Biomarkers: the next generation. Nature Reviews Drug Discovery 9: 415.
16. Williams SA, Slavin DE, Wagner JA, Webster CJ, (2006) A cost-effectiveness approach to the qualification and acceptance of biomarkers. Nature Reviews Drug Discovery 5: 897-902.